BioLife Solutions, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Roderick de Greef
- Full Time Employees
- 155
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 3303 Monte Villa Parkway Bothell WA United States of America 98021
- IPO Date
- Nov 22, 1989
- CIK
- 0000834365
- Website
- biolifesolutions.com
- Similar Companies
- Business
- BioLife Solutions, Inc. specializes in providing advanced biopreservation tools, closed-system cell processing technologies, and workflow solutions primarily for the cell and gene therapy (CGT) industry. Its core product portfolio includes proprietary cryopreservation media such as CryoStor®, non-frozen storage solutions like HypoThermosol® FRS, pathogen-reduced human platelet lysates under the T-Liven PR® brand, and automated closed systems for cell handling such as the Signata CT-5 automated aliquoting instrument. BioLife's solutions are designed to maintain cell integrity, optimize cell culture conditions, streamline bioprocessing workflows, and support regulatory compliance across the R&D, clinical trial, and commercial production stages. The company serves biotechnology and pharmaceutical companies engaged in developing cell and gene therapies, operating predominantly in the United States with global market reach. Founded in 1995 and headquartered in Bothell, Washington, BioLife Solutions has recently undergone significant strategic shifts to focus on its proprietary cell processing platform by divesting its cold chain logistics subsidiary, Evo, and biostorage subsidiary, SciSafe, in all-cash transactions completed in 2024. This refocus has resulted in 27-29% projected revenue growth for 2025, driven by strong recurring demand in its core cell processing consumables business. The company also opened the Aby J. Mathew Center for Biopreservation Excellence at its Bothell campus in 2025, which advances next-generation cryopreservation methods and training while integrating proprietary ice recrystallization inhibitor technology to enhance therapeutic cell preservation. These moves heighten BioLife's emphasis on innovation within CGT biopreservation and streamline its product offerings for greater long-term growth potential. Additionally, BioLife Solutions reported strong financial results in 2025 with cell processing revenues up 33% year-over-year and a notable increase in gross margins, reflecting operational efficiency and market expansion. The company also completed the divestiture of its hemostatic device business, Biolife Delaware, acquired by Merit Medical Systems for approximately $120 million earlier in 2025. These strategic actions collectively underscore BioLife's commitment to being a specialist supplier of high-margin, recurring-revenue bioprocessing consumables and technology solutions essential to the evolving CGT landscape. Overall, BioLife Solutions operates in the life sciences industry segments of biopreservation and cell therapy manufacturing, targeting developers and manufacturers of transformative cell and gene therapies with a comprehensive product portfolio and an innovation-driven growth strategy centered in North America and extending internationally. The company leverages proprietary technology platforms and close customer collaborations to enable advanced bioprocessing and help commercialize next-generation cell-based therapies.
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of BioLife Solutions, Inc. (NASDAQ: BLFS)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of BioLife Solutions, Inc. (NASDAQ: BLFS)
Shareholder Alert: Ademi LLP investigates whether BioLife Solutions, Inc. is obtaining a Fair Price for Public Shareholders
Shareholder Alert: Ademi LLP investigates whether BioLife Solutions, Inc. is obtaining a Fair Price for Public Shareholders
BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLife Solutions, Inc. is Obtaining a Fair Price for its Shareholders
Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition
BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLife Solutions, Inc. is Obtaining a Fair Price for its Shareholders
Repligen to buy cell therapy maker BioLife in $1.5 billion deal
Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media
BioLife Solutions Inc (BLFS) Stock Up 3.1% and Still Undervalued -- GF Score: 73/100
BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript
BioLife Solutions, Inc. (BLFS) Tops Q1 Earnings and Revenue Estimates
BioLife Solutions Reports First Quarter 2026 Financial Results
4 Medical Product Stocks to Buy From a Challenging Industry
BioLife Solutions (NASDAQ:BLFS) Stock Crosses Below 200 Day Moving Average – Time to Sell?
BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase